An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

AIDS

Volumn 17, Issue 1, 2003, Pages

  Nelson, M ^a   Portsmouth, S ^a   Stebbing, J ^a   Atkins, M ^a   Barr, A ^a   Matthews, G ^a   Pillay, D ^b   Fisher, M ^c   Bower, M ^a   Gazzard, B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Hepatitis B; HIV 1; Lamivudine; Resistance mutation; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; PRIORITY JOURNAL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0037414988     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200301030-00002     Document Type: Article

References (21)

1. Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, et al. Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984, 101:795-797.
2. Kane MA. Progress on the control of hepatitis B infection through immunisation. Gut 1993, 34:S10-S12.
3. Fact sheets: hepatitis B. Genva: WHO, October 2000.
4. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999, 12:81-95.
5. Lok ASF. Chronic hepatitis B. N Engl J Med 2002, 346:1682-1683.
6. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61-68.
7. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicarcy C, Rubin M, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657-1661.
8. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV infected men. Ann Intern Med 1996, 125:705-712.
9. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus infected patients. Hepatology 1999, 30:1302-1306.
10. Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S, et al. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antiviral News 1998, 6:167-169.
11. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients co-infected with HBV and human immunodeficiency virus. J Clin Microbiol 1999, 37:3013-3016.
12. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistance hepatitis B virus: an open-label pilot study. Lancet 2001, 358:718-723.
13. Robbins BL, Srinivas RV, Kim C, Bischofberger N. Fridland A, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis (isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998, 42:612-617.
14. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-weeks, randomised, double-blind study. AIDS 2002, 16:1257-1263.
15. Yokota T, Conno K, Chonan E, Mochizuki S, Kojima K, Shigeta S and de Clerq E. Comparitive activities of several nucleoside analogues against duck hepatitis B virus in vitro. Antimicrob Agents Chemother 1990, 34:1326-1330.
16. Cooper D, Cheng A, Coakley D, Sayre J, Zhong L, Chen SS, et al. Anti-HBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 124].
17. Lopez VA, Bourne EJ, Lutz MW, Condreay LD. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002, 40:1972-1976.
18. Jardi R, Buti M, Rogriguez-Frias F, Cotrina M, Costas X, Pascual C, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999, 83:181-187.
19. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002, 346:1706-1713.
20. Di Bisceglie AM. Combination therapy for hepatitis B. Gut 2002, 50:443-445.
21. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomised controlled trial. JAMA 1999, 282:2305-2312.